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characteristics of the infection in humans and provide clear end
points that allow statistical comparisons between different ther-
apeutic regimens, but their implementation is complex and they
involve a considerable investment of time and money. To eval-
uate effortlessly the in vivo efficacy of different antimicrobial
treatments for MRSA and GISA infections, we have developed
a modified model of mouse peritonitis, using clinical strains of
S. aureus with different susceptibilities to -lactams and gly-
copeptides. The mouse peritonitis model is straightforward,
rapid, and easily reproducible, and has been widely used in test-
ing antibiotics in vivo8,11,13–16,18,23,26; however, although it has
been used for the study of S. aureus infections,11,16,18,23,26 only
a few comparative therapeutic studies have been reported. In
this particular study, we performed the standardization of the
model and assessed the comparative efficacy of monotherapy
with cloxacillin, cefotaxime, vancomycin, and teicoplanin
against the infection caused by four S. aureus strains.
INTRODUCTION
GLYCOPEPTIDES ARE CONSIDERED the antibiotics of choice forthe treatment of moderate to severe methicillin-resistant
Staphylococcus aureus (MRSA) infections. However, the emer-
gence of S. aureus strains with decreased susceptibility to these
antibiotics is a matter of concern.2,3,9,10,12,20,29,35,36 Although
the clinical relevance of glycopeptide-intermediate S. aureus
(GISA) is controversial due to the lack of controlled studies,
the poor outcome obtained using vancomycin in some difficult-
to-treat infections such as endocarditis or orthopedic surgical
infections1,5 suggests that glycopeptide therapy may be subop-
timal in this setting. To date, experimental studies assessing the
best treatment of GISA infections have been scarce and incon-
clusive.5 Rabbit endocarditis or foreign body infection in rats
or mice have been mostly used to study S. aureus infections
and alternative therapies. These models closely simulate the
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ABSTRACT
In recent years, the emergence of Staphylococcus aureus strains with reduced susceptibility to glycopeptides
has raised considerable concern. We studied the efficacy of vancomycin and teicoplanin, as well as cloxacillin
and cefotaxime, against the infection caused by four S. aureus strains with different glycopeptide and -lac-
tam susceptibilities (strains A, B, C, and D; MICs for vancomycin of 1, 2, 4, and 8 g/ml respectively), using
a modified model of mouse peritonitis. This optimized model appeared to be straightforward and reproducible,
and was able to detect low differences in bacterial killing between antibiotics and also between different S.
aureus strains. Bactericidal activities in peritoneal fluid for vancomycin, teicoplanin, cloxacillin, and cefo-
taxime decreased from 2.98, 2.36, 3.22, and 3.57 log10 cfu/ml, respectively, in infection by strain A
(MICs for vancomycin and cloxacillin of 1 and 0.38 g/ml, respectively) to 1.22, 0.65, 1.04, and 0.24
in peritonitis due to strain D (MICs for vancomycin and cloxacillin of 8 and 1,024 g/ml). Our data confirm
the superiority of -lactams against methicillin-susceptible S. aureus and show that bactericidal activity of
glycopeptides decreases significantly with slight increases in MICs; this finding suggests a reduced efficacy of
glycopeptides in the treatment of serious glycopeptide-intermediate S. aureus infections.
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MATERIALS AND METHODS
Bacterial strains
Four staphylococcal clinical strains with different suscepti-
bilities to glycopeptides and -lactams were studied. Strains
HUB 954 (strain A), HUB 284 (strain B), and HUB 783 (strain
C) were isolated in our hospital and strain Mu 50 (ATCC
700699) (strain D) was isolated in Japan in 1997 and described
as the first GISA strain.10 Strain C, belonging to the Iberian
clone, had heterogeneous resistance to vancomycin (HRV),
growing on 4 g/ml Müeller–Hinton plates with a frequency
of subpopulations of 3.6  106 cfu/ml1. MICs of strains A, B,
C, and D were determined by the standard macrodilution
method.24 Values of MICs are shown in Table 1.
Inoculum preparation
Colonies from fresh overnight cultures on 5% blood agar
plates were resuspended and grown for 4–6 hr at 37°C in TSB
medium. Immediately before inoculation, cultures in TSB were
centrifuged and resuspended in sterile saline, adjusted to an op-
tical density equal to 0.5 McFarland (108 cfu/ml) and then di-
luted to the appropriate size. Inoculum sizes from 106 to 108
cfu/ml were tested.
Mouse peritonitis model
The animal studies were approved by the Ethical Commit-
tee for Animal Experiments at the University of Barcelona. The
mouse peritonitis model was a modified version of a previously
described protocol.8,13,14 Two different mouse strains were
tested: Outbred, female, ICR CD-1 mice (8 weeks; 30
grams) and inbred, female, C57BL/6 mice (6 weeks; 14–16
grams). Mice were kept 10 to a cage and had food and water
ad libitum. Inoculation was performed by intraperitoneal (i.p.)
injection of 0.5 ml of the inoculum with a 26-gauge syringe.
The inoculum consisted of a staphylococcal suspension with
5% (wt/vol) mucin in sterile saline, which enhances the basal
virulence of bacteria by inhibiting the local macrophage sys-
tem, and renders the mice susceptible to infection. In the first
stage of the study, the experimental design was standardized,
prior to the pharmacokinetic and antibiotic therapy studies.
Mouse strain, inoculum size, and virulence of different bacter-
ial strains were evaluated.
Different time points were tested to study the evolution of
the infection and appropriate time points were set for starting
therapy. Groups of mice were killed at 4, 8, 16, and 24 hr post-
inoculation to obtain blood and peritoneal fluid (PF) samples
as described below. Bacterial counts and bacteremia were de-
termined for each mouse and time point. Mortality was also as-
sessed.
Sample collecting and processing
At each time point, for all experiments, mice were anes-
thetized i.p. with 40 l of ketamine/xylazine 10:1 (100 mg/kg
Ketamine and 10 mg/kg Xylacine) and a peritoneal wash was
performed by injecting 2 ml of sterile saline i.p. followed by a
1-min external massage of the abdomen. Immediately, 0.1 ml
of blood was withdrawn by cardiac puncture, and animals were
then killed by cervical dislocation. The abdomen was opened
and 0.2 ml of PF was recovered from the peritoneum using an
aseptic technique. PF samples were used to perform direct and
10-fold diluted cultures, which were plated (0.1 ml) on 5%
sheep blood TSA plates and incubated for 24 hr at 37°C to de-
termine bacterial counts. The detection limit using this method
was 101 cfu/ml; a value of 0.9 log cfu/ml was assigned to the
first sterile culture and 0 to the subsequent ones. To avoid car-
ryover antimicrobial agent interference, the sample was placed
on the plate in a single streak down the center and allowed to
absorb into the agar until the plate surface appeared dry; the in-
oculum was then spread over the plate. Plates were incubated
overnight at 37°C. Blood cultures were also performed. Imme-
diately after cardiac puncture, blood samples (100 l) were cul-
tured in Trypticase soy broth for 24 hr at 37°C, and then 100
l of the cultured broth were plated in TSA plates and incu-
bated again for 24 hr to assess bacterial growth. Bacteremia was
expressed on the basis of blood cultures. Mortality was also ex-
pressed qualitatively.
Pharmacokinetics
Pharmacokinetic studies were performed to select dose reg-
imens that result in serum concentrations similar to those in hu-
mans. All antimicrobials were administered subcutaneously.
Groups of 20–22 healthy mice were used for each antibiotic
pharmacokinetic study. A single weight-adjusted dose of the
antibiotic was administered to each animal, following previous
pharmacokinetic experimental studies.15,19,22,27,28,31,37,38
After antibiotic administration and at different time points,
sets of 3 animals were anesthetized i.p. with appropriate doses
of ketamine/xylacine, and blood samples (400–500 l) were
obtained by an incision in the periorbital plexus of the eye.
Blood was centrifuged and serum stored at 80°C until analy-
sis. Pharmacokinetic and pharmacodynamic (PK and PD) pa-
rameters were obtained by a computer-assisted method (PK
Functions for Microsoft Excel. J. I. Usansky, A. Desai, and D.
Tang-Liu, Department of Pharmacokinetics and Drug Metabo-
lism, Allergan, Irvine, CA 92606) after determination of an-
tibiotic concentration at the different time points. The parame-
ters calculated were: peak drug concentration in serum (Cmax),
elimination half-life (T1/2), area under the concentration–time
curve (AUC), inhibitory quotient (IQ; IQ  Cmax/MIC), and
time above the MIC of the drug concentration in serum (T 
MIC). Based on previous studies,6,15,16 human data,7,21,30 and
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TABLE 1. MICS (G/ML) OF S. AUREUS
STRAINS USED IN THE STUDY
MIC (g/ml)a
Strain A Strain B Strain C Strain D
Antibiotic (MSSA) (MRSA) (HRV) (GISA)
Cloxacillin 0.38 512 1,024 1,024
Cefotaxime 0.5 1,024 1,024 2,048
Vancomycin 1 2 4 8
Teicoplanin 0.5 1 8 8
aMSSA, Methicillin-susceptible S. aureus; MRSA, methi-
cillin-resistant S. aureus; HRV, heterogeneous resistance to
vancomycin; GISA, glycopeptide-intermediate S. aureus.
the PK and PD parameters obtained, doses administered to mice
were finally selected: vancomycin 30 mg/kg per 4 hr (daily dose
of 180 mg/kg), teicoplanin 40 mg/kg per 24 hr (daily dose of
40 mg/kg), cloxacillin 160 mg/kg per 2 hr (daily dose of 1.6
g/kg), and cefotaxime 200 mg/kg per 2 hr (daily dose of 2 g/kg).
Therapeutic experiments
Once the experimental design of the animal model was fi-
nalized, therapeutic experiments were performed. Four hours
after inoculation, antibiotic therapy was initiated (hour 0). Van-
comycin, teicoplanin, cloxacillin, or cefotaxime were adminis-
tered as single regimens using the antibiotic schedule described
above. At hour 0, 2 mice were killed and used as controls.
Groups of 8 mice were then randomized to different therapeu-
tic regimens (n  6) and control group (n  2). Antibiotic
treatment or placebo was administered for 24 hr and mice were
killed at that time point to obtain blood and PF samples. Ther-
apeutic experiments were repeated several times to achieve a
minimum number of animals in all groups that allowed statis-
tical analysis.
Antibiotic assays
Antibiotic assays were performed in duplicate. The serum
concentrations of vancomycin and teicoplanin were determined
by fluorescent polarization immunoassay (FPIA) using a TDx
analyzer (ABBOTT CIENTÍFICA, S.A., Diagnostics Division,
Costa Brava 13, 28034 Madrid, Spain); minimal detectable con-
centrations were 2.0 g/ml for vancomycin and 1.7 g/ml for
teicoplanin. Serum concentrations of cloxacillin and cefotaxime
were determined by the disk diffusion bioassay method,4 using
S. aureus ATCC 29213 and E. coli ATCC 25922, respectively,
as test organisms. The minimal detectable concentration was
0.5 g/ml for cloxacillin and 1 g/ml for cefotaxime.
Statistical analysis
All bacterial count data were checked for normal distribu-
tion (Kolmogorov–Smirnov test). Analysis of variance
(ANOVA) with the Scheffé post hoc test was used to analyze
multiple comparisons among therapeutic and control groups in
every strain. Also comparisons among strains were made by us-
ing ANOVA (with Tukey post hoc test). The two-tailed Fisher’s
exact test was used for categorical data (survival, bacteremia).
A linear regression was performed to assess correlation between
in vivo vancomycin efficacy (bacterial count) and vancomycin
susceptibility of the four strains (MICs).
RESULTS
Standardization of the model
An inoculum of 106 cfu/ml of S. aureus strain A was used
to compare mouse strains. The results of the immunocompetent
inbred C57BL/6 mouse strain were more homogeneous than
those of its outbred counterpart ICR CD-1. Dispersion in bac-
terial count data obtained at 4 and 24 hr post-inoculation was
significantly higher for ICR CD-1, whereas the mean bacterial
count was higher for C57BL/6 (Fig. 1A). Bacteremia was higher
in the C57BL/6 strain: 100% at 4 and 24 hr post-inoculation
for C57BL/6 and 71% and 80% at 4 and 24 hr, respectively,
for ICR CD-1. Mortality at 24 hr post-inoculation was 68%
(n  19) for C57BL/6 and 25% (n  8) for ICR CD-1. Inocu-
lums from 106 to 108 cfu/ml of S. aureus strains A and C were
compared in the C57BL/6 mice. The 108 cfu/ml inoculum was
rejected because mortality was 100% less than 16 hr post-in-
oculation. Bacterial concentration at 4, 8, and 24 hr post-inoc-
ulation did not show differences between 106 and 107 inocu-
lums or between bacterial strains A and C. Bacteremia at 24 hr
post-inoculation was lower in mice infected with a 106 cfu/ml
inoculum (72%) than in those infected with a 107 cfu/ml in-
oculum (100%, as mentioned above). Mortality was the para-
meter that varied most according to inoculum size: 8 hr post-
inoculation, it was 72% (n  22) with the 107 cfu/ml inoculum,
but zero (n  8) with the 106 cfu/ml inoculum. At 24 hr post-
inoculation, mortality was 100% (n  13) and 68% (n  19)
for 107 and 106 cfu/ml inoculums, respectively (Fig. 1B). So
the final experimental design for therapeutic studies included
C57BL/6 mice and inoculum sizes of 5  106 to 5  107 cfu/ml
depending on bacterial strain. Therapy was initiated 4 hr post-
inoculation to avoid early mortality.
Pharmacokinetics
Pharmacokinetic and pharmacodynamic parameters of an-
tibiotics used in the experiments are shown in Table 2. T1/2 ob-
tained for -lactams in mice is extremely short, and so the in-
terdose time for these antibiotics was also very short. Although
the serum peak was very high for cefotaxime and cloxacillin,
T  MIC for strains B, C, and D was 0. Only for strain A did
the T  MIC of -lactams reach 90–100%. Vancomycin
showed a high serum peak and T  MIC ranging from 45% to
90% depending on the strain. Finally, teicoplanin achieved a
very high AUC (700 g/hr per ml) due to its high serum peak
and long T1/2.
Antibiotic efficacy: bacterial clearance in peritoneal
fluid, bacteremia, and mortality
Initial bacterial counts in PF (mean  SD), corresponding to
hour 0 of the control group for the different strains were: 7.62 
0.37 (n  23) for strain A, 7.05  0.43 (n  15) for strain B,
7.04  0.55 (n  28) for strain C, and 7.02  0.35 (n  13) for
strain D. Bacteremia in control animals at 0 and 24 hr, expressed
as percentage of positive blood cultures, was 100% for all
strains. Mortality of control mice at 24 hr differed according to
strain: 55% for strain A, 22% for strain B, 62% for strain C,
and 21% for strain D.
Bacterial clearance in PF after 24 hr therapy for strains A,
B, C, and D is shown in Fig. 2; n  6 for all therapeutic groups
in all strains and n  12 for 24-hr control groups of all strains.
In strain A peritonitis, cloxacillin and cefotaxime were bacte-
ricidal at 24 hr. Vancomycin and teicoplanin showed slightly
lower activity than -lactams, although the difference was not
significant. All therapies had significantly lower bacterial
counts than the control group. All treated animals survived.
Bacteremia at 24 hr for cloxacillin and cefotaxime treatments
was 0%, but 25% for vancomycin and 100% for teicoplanin.
For strain B, vancomycin and teicoplanin achieved a signif-
icantly higher reduction in bacterial count than -lactams, in
which the decrease was minimal. There was no statistically sig-
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nificant difference between the -lactam and the control group.
No mortality was observed in any treatment group. Vancomycin
reduced bacteremia at 24 hr to zero and teicoplanin to 50%.
Bacteremia fell to 80% with cefotaxime, but remained at 100%
at 24 hr with cloxacillin.
In strain C experiments, only vancomycin was able to reduce
bacterial counts that differed significantly from those of the con-
trol group. It also differed significantly from cefotaxime, which
showed an increase in bacterial count at 24 hr, and was totally
ineffective. Mortality for cefotaxime-treated mice was 66%,
whereas survival was 100% in the other treatment groups.
Cloxacillin and cefotaxime were not able to reduce bacteremia.
Teicoplanin decreased bacteremia slightly to 83% and van-
comycin reduced it to 33%.
Finally, in strain D experiments, vancomycin showed only
moderate activity, lower than that achieved in strain C. Tei-
coplanin reduced the bacterial count slightly, showing lower ac-
tivity than cloxacillin, and less activity also than that achieved
with strain C. The activity of cloxacillin was slightly higher
than that obtained for strains B and C. All treated animals sur-
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FIG. 1. (A) Comparison of data dispersion of bacterial count in PF between ICR (open symbols) and C57BL/6 (solid symbols)
mouse strains at different time points. Each symbol represents one mouse. Solid squares and triangles linked by lines represent
the respective means of C57BL/6 and ICR. (B) Survival at 4, 8, 12, and 24 hr post-inoculation of C57BL/6 mice with peritoni-
tis due to S. aureus. Comparison between 107 (hatched columns) and 106 (gray columns) cfu/ml inoculums.
A
B
vived, except those treated with cefotaxime; cefotaxime was in-
effective, and presented a mortality of 14% at 24 hr. Van-
comycin and cloxacillin reduced bacteremia to 28.6%, whereas
teicoplanin and cefotaxime achieved no reduction.
Comparison of glycopeptide therapy between the four strains
in the study is shown in Fig. 3; its efficacy was significantly
lower with infections due to strains C and D (HRV, GISA) than
with infections due to strains A and B.
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TABLE 2. PHARMACOKINETIC AND PHARMACODYNAMIC PARAMETERS OF ANTIBIOTICS USED IN THE EXPERIMENTS
Antibiotics
Parameter Cloxacillin Cefotaxime Vancomycin Teicoplanin
Dose 160 mg/kg 200 mg/kg 30 mg/kg 40 mg/kg
Cmax (g/ml) 163.5 162.3 44 148
t1/2 (hr) 0.35 0.19 0.56 3.26
AUC (g/hr per ml) 116.25 76.4 45.4 729
IQ (Cmax/MIC)
Strain A 430.13 324.68 44.01 296.20
Strain B 0.64 0.63 22.01 148.10
Strain C 0.64 0.63 11.00 18.51
Strain D 0.64 0.63 5.50 18.51
t  MIC (hr) [%]
Strain A 3.4 [100] 1.78 [80] 3.47 [87] 25.94 [100]
Strain B 0 [--] 0 [--] 2.91 [73] 22.68 [95]
Strain C 0 [--] 0 [--] 2.35 [59] 12.91 [54]
Strain D 0 [--] 0 [--] 1.79 [48] 12.91 [54]
FIG. 2. Bacterial killing rates in peritoneal fluid after 24 hr of therapy for strains A (A), B (B), C (C), and D (D). Results are ex-
pressed as differences in mean bacterial counts between the different groups at 24 hr of treatment and controls at 0 hr (log10 cfu/ml
(24–0 hr). Mean bacterial counts  SD at 24 hr for the different strains were, for strain A: CLX 4.40  0.32, CTX 4.05  0.65, VAN
4.64  0.46, TEI 5.26  0.65, and Control (CTRL) 6.95  0.62; for strain B: CLX 6.26  0.47, CTX 6.35  0.67, VAN 4.66 
0.44, TEI 4.73  0.63, and Control (CTRL) 7.01  0.62; for strain C: CLX 6.08  0.90, CTX 7.59  0.38, VAN 5.19  0.39, TEI
6.02  0.88, and Control (CTRL) 7.18  0.73; and for strain D: CLX 5.98  0.69, CTX 7.26  0.45, VAN 5.80  0.46, TEI 6.37 
0.87, and Control (CTRL) 7.02  0.75. n  6 for all therapeutic groups and n  12 for control groups at 24 hr.
A B
DC
DISCUSSION
In general, previous experimental studies with the S. aureus
mouse peritonitis model have not focused on comparison of dif-
ferent antibiotic regimens. We developed a modified version of
the model previously described, evaluating variables involved
in the experimental design to obtain a model that was suffi-
ciently sensitive for detecting differences in efficacy among dif-
ferent antibiotic regimens. Results for mean bacterial count,
bacterial count dispersion, and bacteremia suggested that the
C57BL/6 mouse strain performed better, showing more sus-
ceptibility to infection and also providing more homogeneous
findings. Among the different parameters used, the bacterial
count of peritoneal fluid was the most useful to assess antibi-
otic efficacy, whereas survival was less sensitive for compar-
isons between different antibiotics in this model. Therefore, we
sought an inoculum size that could produce a high bacterial
count in peritoneal fluid, high bacteremia, and low mortality
during the first hours after inoculation. While bacterial counts
in peritoneal fluid of 7–8 log10 cfu/ml and 100% bacteremia
were found using inoculums of both 106 and 107 cfu/ml, mor-
talities ranged from 21% to 62%, depending on the strain, re-
flecting the virulence of the model. We therefore used 5–9 
106 as the inoculum size of choice for strain A and 1–5  107
cfu/ml for strains B, C, and D to obtain a similar mortality rate.
The mouse peritonitis model was highly reproducible, and it
was easier to perform and cheaper than other models used in
experimental S. aureus-related infections.
Antibiotic dosing regimens were chosen to obtain appropri-
ate PK/PD parameters that simulate those in humans.6,7,21 Van-
comycin at a dose of 30 mg/kg reached a good peak in mice
serum (within the range of that in humans), with high IQ val-
ues for strains A and B, within the recommended values for
strain C and slightly below that value for strain D. This dose
was administered every 4 hr (final dose of 180 mg/kg per day)
to maintain a good T  MIC value, which was high for strains
A and B and below 50% of interdose time for strains C and D.
Efficacy of vancomycin decreased from strain A to D, show-
ing a good correlation with the MICs of the different strains
and the PK/PD parameters obtained. Teicoplanin at 40 mg/kg
achieved a serum peak and trough similar to those in humans
and, as expected from its long elimination half-life, showed a
very high AUC. It could therefore be administered in a single
daily dose. Higher IQs than vancomycin, (minimal 10 for
strain D) and T  MIC from 100% for strain A to 40% for
strain D confirmed an optimal PK/PD profile, similar to that in
humans.
Teicoplanin showed good efficacy for strains A and B, but
only moderate for strains C and D, in accordance with its
pharmacodynamic profile, but with some differences with re-
spect to vancomycin. Vancomycin showed slightly improved
activity than teicoplanin in experiments with strains A and
B; this better efficacy is more evident for strains C and D al-
though no significant differences were found between the two
therapies. Thus, teicoplanin presented better PK/PD profiles
than vancomycin, but it was not more effective in vivo, as
others have already reported.27,38 It is interesting how this
point becomes more apparent with GISA strains, in which tei-
coplanin therapy was clearly less effective than vancomycin.
Recently, Pavie et al. have reported the impact of the GISA
phenotype when using teicoplanin in therapy for experimen-
tal endocarditis,25 an observation that is in agreement with
our results. High levels of protein binding and low penetra-
tion in some tissues have been proposed as possible causes
for teicoplanin failure in some clinical and experimental in-
fections.15,16,25
Cloxacillin and cefotaxime showed bactericidal efficacy in
the treatment of peritonitis due to strain A, as was expected
from their PK/PD profiles. On the other hand, vancomycin and
teicoplanin showed good activity but were not bactericidal at
24 hr. Our results corroborate previous reports that glycopep-
tides are less bactericidal than -lactams in the treatment of se-
rious infections such as endocarditis.5,17,32 Cefotaxime and
cloxacillin preserved a slight activity against strain B despite
the fact that their T  MIC was 0, and, more surprisingly,
cloxacillin retained a moderate activity against strains C and D,
a finding that was not consistent with its pharmacodynamic pa-
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FIG. 3. (A) Comparison of vancomycin and teicoplanin bac-
terial killing rates at 24 hr among S. aureus strains A, B, C, and
D. Results are expressed as log10 cfu/ml (24–0 hr). Mean bac-
terial counts  SD at 24 hr for the different strains were: strain
A, VAN 4.64  0.46, TEI 5.26  0.65; strain B, VAN 4.66 
0.44, TEI 4.73  0.63; strain C, VAN 5.19  0.39, TEI 6.02 
0.88; and strain D, VAN 5.80  0.46, TEI 6.37  0.87. n  6
for all groups. (B) Linear regression between vancomycin sus-
ceptibility, expressed as the MIC of the different strains (x axis)
and vancomycin efficacy, expressed as bacterial counts (log
cfu/ml) of vancomycin-treated groups (y axis). Each point rep-
resents one mouse.
rameters. A partial explanation for this observation may be the
reciprocal loss of resistance to oxacillin in some strains as van-
comycin MICs increase, as was previously described by Sier-
adzki and Tomasz.33,34 On the one hand, they noted that van-
comycin-resistant S. aureus laboratory-derived mutants reduced
-lactam resistance as increased MICs of the glycopeptides; on
the other, they reported that the acquisition of this resistance to
vancomycin involves the change from the homogeneous to the
heterogeneous methicillin-resistant phenotype. Thus, although
hGISA and GISA strains used in our experiment were still
highly resistant to methicillin on the basis of their MICs, we
can hypothesize that the increasing in vivo efficacy of
cloxacillin may be due to the emergence of subpopulations less
resistant to methicillin, reflecting an early stage in the change
from the homogeneous to the heterogeneous methicillin-resis-
tant phenotype.
The efficacy of vancomycin and teicoplanin to treat peri-
tonitis due to strains B, C, and D decreased progressively. In-
terestingly, percentages of bacteremia increased as killing rates
achieved by glycopeptides decreased. Comparison of gly-
copeptide efficacy among the four strains showed that bacteri-
cidal activity decreased significantly with slight increases in
glycopeptide MICs (Fig. 3A). The linear regression shown in
Fig. 3B underscores this inverse linear relationship between
vancomycin MIC and its efficacy in vivo. This result suggests
that any decrease in glycopeptide susceptibility may have clin-
ical implications, especially in the setting of difficult-to-treat
infections such as endocarditis or orthopedic infection, as has
been previously described.1,5 On the other hand, vancomycin
keeps significant activity compared to controls in strains C and
D (Fig. 3D). Although scarce, this remnant bacteriostatic ac-
tivity could be relevant in the clinical setting, in which van-
comycin can be still useful in relatively mild infections such as
nonnecrotizing skin and soft tissue infections, but not in severe
infections.
In conclusion, this mouse peritonitis model is straightforward
and reproducible. It is able to detect low differences in bacter-
ial killing among antibiotics and also among S. aureus strains
with different methicillin and glycopeptide susceptibilities.
Therefore, this model is particularly useful for comparing the
efficacy of antibiotics against these strains. Although the results
obtained with experimental infections must be interpreted with
caution, our study suggests that heterogeneous resistance to gly-
copeptides and increases in glycopeptide MICs may be associ-
ated with a loss of efficacy in these antibiotics. These findings
help to explain previous reports of therapeutical failures with
infections due to HRV and GISA strains. This experimental
model seems particularly well suited to the task of finding al-
ternative treatments for these infections.
ACKNOWLEDGMENTS
We thank J.M. Ramón, from Hospital de Bellvitge, for his
assistance in statistical analysis. This work was supported by a
research grant from the Fondo de Investigaciones Sanitarias FIS
00/0156 from Ministerio de Sanidad, Spain. A. Domenech was
supported by a grant from the Universitat de Barcelona, and S.
Ribes and A. Montero were supported by grants from the Fun-
dació August Pi i Sunyer. The study was performed without
any financial support from laboratories.
REFERENCES
1. Ariza, J., M. Pujol, J. Cabo, C. Peña, N. Fernández, J. Liñares,
J. Ayats, and F. Gudiol. 1999. Vancomycin in surgical infections
due to methicillin-resistant Staphylococcus aureus with heteroge-
neous resistance to vancomycin. Lancet 353:1587–1588.
2. Centers for Disease Control and Prevention. 2000. Staphylo-
coccus aureus with reduced susceptibility to vancomycin-Illinois,
1999. Morb. Mortal. Wkly. Rep. 48:1165–1167.
3. Centers for Disease Control and Prevention. 1997. Staphylo-
coccus aureus with reduced susceptibility to vancomycin-United
States, 1997. Morb. Mortal. Wkly. Rep. 46:765–766.
4. Chapin-Robertson, K., and S.C. Edberg. 1991. Measurements
of antibiotics in human body fluids: techniques and significance.
In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams
and Wilkins, New York, pp. 295–366.
5. Climo, W.M., R.L. Patron, and G.L. Archer. 1999. Combina-
tions of vancomycin and -lactams are synergistic against staphy-
lococci with reduced susceptibilities to vancomycin. Antimicrob.
Agents Chemother. 43:1747–1753.
6. Craig, W.A. 1998. Pharmacokinetic/pharmacodynamic parame-
ters: rationale for antibacterial dosing of mice and men. Clin. In-
fect. Dis. 26:1–12.
7. Fekety, R. 1995. Vancomycin and Teicoplanin. In G.L. Mandell,
J.E. Bennett, and R. Dolin (ed.), Principles and practice of infec-
tious diseases, 4th ed. Churchill Livingston, New York, pp. 346–
354.
8. Frimodt-Moller, N. 1993. The mouse peritonitis model: present
and future use. J. Antimicrob. Chemother. 31(Suppl D):55–60.
9. Hiramatsu, K., N. Aritaka, H. Hanaki, S. Kawasaki, Y. Hosoda,
S. Hori, Y. Fukuchi, and I. Kobayashi. 1997. Dissemination in
Japanese hospitals of strains of Staphylococcus aureus heteroge-
neously resistant to vancomycin. Lancet 350:1670–1673.
10. Hiramatsu, K., H. Hanaki, T. Ino, K. Yabuta, T. Oguru, and
F. C. Tenover. 1997. Methicillin-resistant Staphylococcus aureus
clinical strain with reduced vancomycin susceptibility. J. Antimi-
crob. Chemother. 40:135–136.
11. Hirschl, A., G. Stanek, and M. Rotter. 1984. Effectiveness of
cefamandole against methicillin-resistant strains of Staphylococcus
aureus in vitro and in experimental infections. J. Antimicrob.
Chemother. 13:429–435.
12. Kim, M. N., C.H. Pai, J.H. Woo, J.S. Ryu, and K. Hiramatsu.
2000. Vancomycin intermediate Staphylococcus aureus in Korea.
J. Clin. Microbiol. 38:3879–3881.
13. Knudsen, J.D., N. Frimodt-Moller, and F. Espersen. 1995. Ex-
perimental Streptococcus pneumoniae infection in mice for study-
ing correlation of in vitro and in vivo activities of penicillin against
pneumococci with various susceptibilities to penicillin. Antimi-
crob. Agents Chemother. 39:1253–1258.
14. Knudsen, J.D., N. Frimodt-Moller, and F. Espersen. 1998. Phar-
macodynamics of penicillin are unaffected by bacterial growth
phases of Streptococcus pneumoniae in the mouse peritonitis
model. J. Antimicrob. Chemother. 41:451–459.
15. Knudsen, J.D., K. Fuursted, F. Espersen, and N. Frimodt-
Moller. 1997. Activities of vancomycin and teicoplanin against
penicillin-resistant pneumococci in vitro and in vivo and correla-
tion to pharmacokinetic parameters in the mouse peritonitis model.
Antimicrob. Agents Chemother. 41:1910–1915.
16. Knudsen, J.D., K. Fuursted, S. Raber, F. Espersen, and N.
Frimodt-Moller. 2000. Pharmacodynamics of glycopeptides in the
mouse peritonitis model of Streptococcus pneumoniae or Staphy-
DOMENECH ET AL.352
lococcus aureus infection. Antimicrob. Agents Chemother. 44:
1247–1254.
17. Levine, D.P., B.S. Fromm, and B.R. Reddy. 1991. Slow response
to vancomycin or vancomycin plus rifampin in methicillin-resis-
tant Staphylococcus aureus endocarditis. Ann. Intern. Med.
115:674–680.
18. Mannisto, P.T., H. Hanhijarvi, A. Havas, A. Vuorela, H. Ko-
mulainen, and V. Rauramaa. 1989. Efficacy of erythromycin
acistrate (2	-acetyl erythromycin stearate) and erythromycin
stearate in experimental infections in mice. J. Pharmacol. Exp.
Ther. 250:1028–1033; erratum in J. Pharmacol Exp. Ther. 251:
1246–1247, 1989.
19. Mattie, H., L.C. Zhang, E. van Strijen, B.R. Sekh, and A.E.
Douwes-Idema. 1997. Pharmacokinetic and pharmacodynamic
models of the antistaphylococcal effects of meropenem and
cloxacillin in vitro and in experimental infection. Antimicrob.
Agents Chemother. 41:2083–2088.
20. McManus, J. 1999. Vancomycin resistant staphylococcus reported
in Hong Kong. Br. Med. J. 318:626
21. Monroe, S.G., and R. Polk. 1999. Teicoplanin; vancomycin. In
V.L. Yu, T.C. Merigan Jr., and S.L. Barriere (ed.), Antimicrobial
therapy and vaccines. Williams and Wilkins, Baltimore, MD, pp.
978–981 and 1007–1018.
22. Nagano, R., K. Shibata, T. Naito, A. Fuse, K. Asano, T.
Hashizume, and S. Nakagawa. 1997. Therapeutic efficacy of BO-
3482, a novel dithiocarbamate carbapenem, in mice infected with
methicillin-resistant Staphylococcus aureus. Antimicrob. Agents
Chemother. 41:2278–2281.
23. Nagl, M., P. Hengster, E. Semenitz, and W. Gottardi. 1999. The
postantibiotic effect of N-chlorotaurine on Staphylococcus aureus.
Application in the mouse peritonitis model. J. Antimicrob.
Chemother. 43:805–809.
24. National Committee for Clinical Laboratory Standards. 2000.
Methods for dilution antimicrobial susceptibility test for bacteria
that grow aerobically. Approved standard, 5th ed., NCCLS Docu-
ment M7-A5, vol. 20, no. 2. National Committee for Clinical Lab-
oratory Standards, Villanova, PA.
25. Pavie, J., A. Lefort, MC. Ploy, L. Massias, F. Chau, L. Garry,
F. Denis, and B. Fantin. 2003. Influence of reduced susceptibil-
ity to glycopeptides on activities of vancomycin and teicoplanin
against Staphylococcus aureus in experimental endocarditis. An-
timicrob. Agents Chemother. 47:2018–2021.
26. Pechere, J.C., B. Marchou, M. Michea-Hamzehpour, and R.
Auckenthaler. 1986. Emergence of resistance after therapy with
antibiotics used alone or combined in a murine model. J. Antimi-
crob. Chemother. 17 (Suppl A):11–18.
27. Peetermans, W.E., J.J. Hoogeterp, A-M. Hazekamp-van
Dokkum, P. van den Broek, and H. Mattie. 1990. Antistaphy-
lococcal activities of teicoplanin and vancomycin in vitro and in
an experimental infection. Antimicrob. Agents Chemother.
34:1869–1874.
28. Pitkin, D.H., B.A. Mico, R.D. Sitrin, and L.J. Nisbet. 1986.
Charge and lipophilicity govern the pharmacokinetics of gly-
copeptide antibiotics. Antimicrob. Agents Chemother. 29:440–444.
29. Ploy, M.C., C. Grelaud, C. Martin, L. de Lumley, and F. De-
nis. 1998. First clinical isolate of vancomycin-intermediate Staphy-
lococcus aureus in a French hospital. Lancet 351:1212.
30. Sábada Díaz de Rada, B., J.R. Azanza Perea., E. García Quet-
glas, and J. Honorato Pérez. 1998. Glucopéptidos: vancomicina
y teicoplanina. In Medicine 7 (72), Ediciones Doyma S. L.,
Barcelona, Spain, p. 3329–3336.
31. Sauve, C., E. Azoulay-Dupuis, P. Moine, C. Darras-Joly, V.
Rieux, C. Carbon, and J. P. Bedos. 1996. Efficacies of cefotaxime
and ceftriaxone in a mouse model of pneumonia induced by two
penicillin- and cephalosporin-resistant strains of Streptococcus
pneumoniae. Antimicrob. Agents Chemother. 40:2829–2834.
32. Small, P.M., and H.F. Chambers. 1990. Vancomycin for Staphy-
lococcus aureus endocarditis in intravenous drug users. Antimi-
crob. Agents Chemother. 34:1227–1231.
33. Sieradzki, K., and A. Tomasz. 1997. Inhibition of cell wall
turnover and autolysis by vancomycin in a highly vancomycin-re-
sistant mutant of Staphylococcus aureus. J. Bacteriol. 179:2557–
2566.
34. Sieradzki, K., and A. Tomasz. 1999. Inactivation of the methi-
cilli resistance gene mecA in vancomycin-resistant Staphylococ-
cus aureus. Microb Drug Resist 5:253–257.
35. Sieradzki, K., R.B. Roberts, S.W. Haber, and A. Tomasz. 1999.
The development of vancomycin resistance in a patient with me-
thicillin-resistant Staphylococcus aureus infection. N. Engl. J. Med.
340:517–523.
36. Smith, T.L., M.L. Pearson, K.R. Wilcox, C. Cruz, M.V. Lan-
caster, B. Robinson-Dunn, F.C. Tenover, M.J. Zervos, J.D.
Band, E. White, and W.R. Jarvis. 1999. Emergence of van-
comycin resistance in Staphylococcus aureus. N. Engl. J. Med.
340:493–501.
37. Tateda, K., K. Takashima, H. Miyazaki, T. Matsumoto, T. Ha-
tori, and K. Yamaguchi. 1996. Noncompromised penicillin-re-
sistant pneumococcal pneumonia CBA/J mouse model and com-
parative efficacies of antibiotics in this model. Antimicrob. Agents
Chemother. 40:1520–1525.
38. Torney, H.L., F.J. Balistreri, M.T. Kenny, and W.D. Cheng.
1991. Comparative therapeutic efficacy of teicoplanin and van-
comycin in normal and in neutropenic mice infected with
Staphylococcus haemolyticus. J. Antimicrob. Chemother.
28:261–269.
Address reprint requests to:
Dr. Alejandro Domenech
Infectious Diseases Service
Hospital Universitari de Bellvitge
c/Feixa Llarga s/n
08907 L’Hospitalet de Llobregat
Barcelona, Spain
E-mail: adomenech@bell.ub.es
GLYCOPEPTIDE EFFICACY IN GISA EXPERIMENTAL INFECTION 353
This article has been cited by:
1. L. Diaz, D. P. Kontoyiannis, D. Panesso, N. D. Albert, K. V. Singh, T. T. Tran, J. M. Munita, B. E. Murray, C. A. Arias. 2013.
Dissecting the Mechanisms of Linezolid Resistance in a Drosophila melanogaster Infection Model of Staphylococcus aureus.
Journal of Infectious Diseases 208:1, 83-91. [CrossRef]
2. Eun Young Choi, Jin Won Huh, Chae-Man Lim, Younsuck Koh, Sung-Han Kim, Sang-Ho Choi, Yang Soo Kim, Mi-Na Kim,
Sang-Bum Hong. 2011. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial
pneumonia. Intensive Care Medicine 37:4, 639-647. [CrossRef]
3. M. E. Pachón-Ibáñez, S. Ribes, M. Á. Domínguez, R. Fernández, F. Tubau, J. Ariza, F. Gudiol, C. Cabellos. 2011. Efficacy
of fosfomycin and its combination with linezolid, vancomycin and imipenem in an experimental peritonitis model caused by a
Staphylococcus aureus strain with reduced susceptibility to vancomycin. European Journal of Clinical Microbiology & Infectious
Diseases 30:1, 89-95. [CrossRef]
4. S. Ribes, M. E. Pachón-Ibáñez, M. A. Domínguez, R. Fernández, F. Tubau, J. Ariza, F. Gudiol, C. Cabellos. 2010. In vitro and
in vivo activities of linezolid alone and combined with vancomycin and imipenem against Staphylococcus aureus with reduced
susceptibility to glycopeptides. European Journal of Clinical Microbiology & Infectious Diseases 29:11, 1361-1367. [CrossRef]
5. Jordi Carratalà, José Alcamí, Elisa Cordero, José M. Miró, José Manuel Ramos. 2008. Investigación en enfermedades infecciosas.
Enfermedades Infecciosas y Microbiología Clínica 26, 40-50. [CrossRef]
6. A. Soriano, F. Marco, J. A. Martinez, E. Pisos, M. Almela, V. P. Dimova, D. Alamo, M. Ortega, J. Lopez, J. Mensa. 2008.
Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of Methicillin-Resistant Staphylococcus aureus
Bacteremia. Clinical Infectious Diseases 46:2, 193-200. [CrossRef]
7. R. N. Jones. 2006. Microbiological Features of Vancomycin in the 21st Century: Minimum Inhibitory Concentration Creep,
Bactericidal/Static Activity, and Applied Breakpoints to Predict Clinical Outcomes or Detect Resistant Strains. Clinical Infectious
Diseases 42:Supplement 1, S13-S24. [CrossRef]
8. H SADER, T FRITSCHE, R JONES. 2005. Antimicrobial activity of daptomycin tested against clinical strains of indicated
species isolated in North American medical centers (2003). Diagnostic Microbiology and Infectious Disease 53:4, 329-332. [CrossRef]
